GRAIL (NASDAQ:GRAL) Trading Up 15.8% – Still a Buy?

GRAIL, Inc. (NASDAQ:GRAL)’s share price rose 15.8% on Tuesday . The company traded as high as $46.16 and last traded at $49.8210. Approximately 467,142 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 1,337,746 shares. The stock had previously closed at $43.03.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on GRAL shares. Guggenheim boosted their price objective on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group decreased their price objective on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday. Morgan Stanley set a $60.00 price objective on GRAIL in a research report on Tuesday. TD Cowen assumed coverage on GRAIL in a research note on Thursday, February 19th. They issued a “hold” rating and a $114.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $90.17.

GRAIL Trading Up 15.8%

The company has a 50 day moving average of $95.65 and a 200 day moving average of $76.60. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -4.49 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The company had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. As a group, sell-side analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Institutional Investors Weigh In On GRAIL

Hedge funds and other institutional investors have recently bought and sold shares of the business. N.E.W. Advisory Services LLC bought a new stake in shares of GRAIL during the fourth quarter worth $26,000. Comerica Bank raised its stake in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of GRAIL during the fourth quarter worth approximately $31,000. Intesa Sanpaolo S.p.A. bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $44,000. Finally, Ankerstar Wealth LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at approximately $45,000.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.